The effect of subconjuctival combined treatment of bevacizumab and triamcinolone acetonide on corneal neovascularization in rabbits

Cornea

Volumn 29, Issue 2, 2010, Pages 192-196

  Kang, Seungbum ^a   Chung, Sung Kun ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Bevacizumab; Cornea; Neovascularization; Triamcinolone

Indexed keywords

BEVACIZUMAB; INTERLEUKIN 6; TRIAMCINOLONE ACETONIDE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; DRUG EFFICACY; NONHUMAN; PHOTOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RABBIT; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODEL; DRUG COMBINATION; INJECTION; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CONJUNCTIVA; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; INJECTIONS; INTERLEUKIN-6; RABBITS; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77649153733     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e3181b1c82f     Document Type: Article

References (34)

1. Dana MR, Steilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996;37: 2485-2494.
2. Chang JH, Gabison EE, Katp T, et al. Corneal neovascularization. Curr Opin Ophthalmol. 2001;12:242-249.
3. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998;43:245-269.
4. Epstein RJ, Stulting RD, Hendricks RL, et al. Corneal neovascularization. Pathogenesis and inhibition. Cornea. 1987;6:250-257.
5. Crum R, Szabo S, Folkman J. A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science. 1985;230:1375-1378.
6. Joussen AM, Kruse FE, Volcker HE, et al. Topical application of methotrexate for inhibition of corneal angiogenesis. Graefes Arch Clin Exp Ophthalmol. 1999;237:920-927.
7. Lipman RM, Epstein RJ, Hendricks RL. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol. 1992;110:405-407.
8. Benelli U, Bocci G, Danesi R, et al. The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res. 1998;67:133-142.
9. D'Amato RJ, Loughnan MS, Flynn E, et al. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91:4082-4085.
10. Deutsch TA, Hughes WF. Suppressive effects of indomethacin on thermally induced neovascularization of rabbit corneas. Am J Ophthalmol. 1979;87:536-540.
11. Sonoda KH, Enaida H, Ueno A, et al. Pars plana vitrectomy assisted by triamcinolone acetonide for refractory uveitis: a case series study. Br J Ophthalmol. 2003;87:1010-1014.
12. Peyman GA, Cheema R, Conway MD, Fang T. Triamcinolone acetonide as an aid to visualization of the vitreous and the posterior hyaloid during pars plana vitrectomy. Retina. 2000;20:554-555.
13. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001; 132:425-427. (Pubitemid 32768624)
14. Danis RP, Bingaman DP, Yang Y, et al. Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide. Ophthalmology. 103: 2099-2104.
15. Murata M, Shimizu S, Horiuchi S, et al. Inhibitory effect of triamcinolone acetonide on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2006;244:205-209.
16. Funatsu H, Yamashita H, Shimizu E, et al. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina. 2001;21:469-477.
17. Shimizu E, Funatsu H, Yamashita H, et al. Plasma level of interleukin-6 is an indicator for predicting diabetic macular edema. Jpn J Ophthalmol. 2002;46:78-83.
18. Wei LH, Kuo ML, Chen CA, et al. Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway. Oncogene. 2003;22:1517-1527.
19. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8: 241-252.
20. Banerjee K, Biswas PS, Kim B, et al. CXCR2-/- mice show enhanced susceptibility to herpetic stromal keratitis: a role for IL-6-induced neovascularization. J Immunol. 2004;172:1237-1245.
21. Rochels R. Animal experiment studies on the role of inflammation mediators in corneal neovascularization. Doc Ophthalmol. 1984;57:215-262.
22. Biswas PS, Banerjee K, Kinchington PR, et al. Involvement of IL-6 in the paracrine production of VEGF in ocular HSV-1 infection. Exp Eye Res. 2006;82:46-54.
23. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Eng J Med. 2004;350:2335-2342.
24. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularization by bevacizumab (Avastin). Br J Ophthalomol. 2007;91:804-807.
25. Bahar I, Kaiserman I, McAllum P, et al. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. 2008;27:142-147.
26. Papathanassiou M, Theodossiadis PG, Liarakos VS, et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model. Am J Ophthalmol. 2008;145:424-431.
27. Kim TI, Kim SW, Kim S, et al. Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin). Cornea. 2008;27:349-352.
28. Oh JY, Kim MK, Shin MS, et al. The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas. Curr Eye Res. 2009;34:85-91.
29. Hurmeric V, Mumcuoglu T, Erdurman C, et al. Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs. Cornea. 2008;27:357-362.
30. Doctor PP, Bhat PV, Foster CS. Subconjunctival bevacizumab for corneal neovascularization. Cornea. 2008;27:992-995.
31. Ebrahem Q, Minamoto A, Hoppe G, et al. Triamcinolone acetonide inhibits IL-6- and VEGF-induced angiogenesis downstream of the IL-6 and VEGF receptors. Invest Ophthalmol Vis Sci. 2006;47:4935-4941.
32. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985;4:531-535.
33. Nikolic L, Friend J, Taylor S, et al. Inhibition of vascularization in rabbit corneas by heparin: cortisone pellets. Invest Ophthalmol Vis Sci. 1986;27: 449-456.
34. Phillips K, Arffa R, Cintron C, et al. Effects of prednisolone and medroxyprogesterone on corneal wound healing, ulceration, and neovascularization. Arch Ophthalmol. 1983;101:640-643.